Rationale, application, and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Merlini G et al. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.191. [Epub ahead of print].

Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Hogan JJ et al. Clin J Am Soc Nephrol. 2016 Jul 14. pii: CJN.03160316. [Epub ahead of print].

Solitary Extramedullary Plasmacytoma of the Maxillary Sinus, Progressing to Smoldering Multiple Myelomawith Multifocal Skeletal Involvement, which Resolved Completely Following Chemotherapy Alone.
Jeyaraj P et al. J Maxillofac Oral Surg. 2016 Jul;15(Suppl 2):229-39. doi: 10.1007/s12663-015-0742-0. Epub 2015 Jan 30.

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up a randomised, controlled, phase 3 trial.
Mateos MV et al. Lancet Oncol. 2016 Jul 8. pii: S1470-2045(16)30124-3. doi: 10.1016/S1470-2045(16)30124-3. [Epub ahead of print].

Early treatment for high-risk smouldering myeloma: has the time come?
Ludwig H et al. Lancet Oncol. 2016 Jul 8. pii: S1470-2045(16)30151-6. doi: 10.1016/S1470-2045(16)30151-6. [Epub ahead of print].

Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Balsman E. J Oncol Pharm Pract. 2016 Jun 29. pii: 1078155216657680. [Epub ahead of print].